VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company's President and Chief Executive Officer, Dr. Mark J. Murray, will present at the Piper Jaffray 22nd Annual Health Care Conference on Tuesday November 30, 2010 at 4:30 pm ET at the New York Palace Hotel in New York City. A webcast of the presentation will be available and can be accessed on the Company's website, www.tekmirapharm.com .

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com . Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8319
CONTACT:  The Equicom Group           Investors           Adam Peeler          416-815-0700 x 225           apeeler@equicomgroup.com          Tekmira Pharmaceuticals          Investors          Ian Mortimer, Executive Vice President and           Chief Financial Officer           604-419-3200             Longview Communications Inc.          Media           David Ryan           604-694-6031           dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo